Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Coulter Partners places Chief Scientific Officer at Slingshot Therapeutics

LONDON, UK  – November 19, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited (“Slingshot”) and is pleased to announce the placement of Dr. John Isaac as Chief Scientific Officer (CSO). Slingshot’s founding CSO Richard Wooster will now transition to a non-executive role as Scientific Advisor and Board member.

Fragment-Based Drug Discovery (FBDD): Workflow, Benefits, and How It’s Shaping the Future of Drug Research

Over four decades since its conception in 1980, Fragment-Based Drug Discovery (FBDD) has emerged as an innovative and efficient approach to modern drug development, showing advantages over traditional high-throughput screening (HTS) methods. By focusing on smaller, simpler molecules, FBDD provides a foundation for developing novel therapeutics, especially for challenging previously “undruggable” targets.

RxCelerate and Constructive Bio Announce Partnership to Advance Next-Generation Therapeutics

Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.

Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.

UK nuclear revolution powers next-generation precision cancer therapies

The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.

Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

Senior Business Development Manager

The United Kingdom Health Security Agency (UKHSA) is a system leader for health security; taking action internationally to strengthen global health security, providing trusted advice to government and the public and reducing inequalities in the way different communities experience and are impacted by infectious disease, environmental hazards, and other threats to health.

Laboratory Technician

EDX Medical Ltd was founded by Professor Sir Chris Evans in early 2022 to provide a range of testing solutions from point of care to laboratory assays in a range of major diseases, including cancer, neurological disorders, cardio-metabolic and infectious diseases. Sir Chris was knighted for his services to the British biotechnology industry and is one of the UK’s leading entrepreneurs and investors, founding dozens of companies.

Device Development Lead - Drug Delivery Systems

TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.

We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.

From Draft to Dossier: The Strategic Art of Medical Writing in MAAs

 

Discover what drives a successful MAA

Join tranScrip’s expert panel as they explore how medical writing lies at the heart of every successful MAA, not as an afterthought, but as the driving force behind clarity, strategy, and collaboration from the very beginning.

The discussion will offer insider perspectives on what makes an exceptional MAA, how to achieve it, and how cross-functional expertise, spanning medical writing, regulatory, medical, and publishing teams, can transform complex data and processes into successful outcomes.

Subscribe to